Treatment(s) already received-Chemotherapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Chemotherapy Posts on Medivizor

Does graft versus host disease affect relapse and survival rates after a stem cell transplant in childhood leukemia?

Posted by on Jul 13, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effect of graft versus host disease on relapse rates in children with acute leukemia. This study concluded that graft versus host disease may protect against relapse, but they did not see an effect on survival. Some background One complication following an allogeneic stem cell transplant (transplant using donor...

Read More

Does radiotherapy improve outcomes for patients with primary breast diffuse large B-cell lymphoma?

Posted by on Jul 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of radiotherapy on the outcomes of rituximab (Rituxan)-treated patients with primary breast diffuse large B-cell lymphoma. This study concluded that radiotherapy has significant therapeutic benefits for these patients. Some background Primary breast diffuse large B-cell lymphoma (DLBCL) is a rare type of...

Read More

Does bendamustine treatment increase risk of infections in non-Hodgkin Lymphoma?

Posted by on Jun 21, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of infection in older patients with indolent non-Hodgkin lymphoma (nHL) treated with bendamustine (Treanda). Researchers concluded that nHL patients treated with bendamustine had increased risk of common bacterial, fungal, and viral infections. Some background Bendamustine is a chemotherapy drug sometimes...

Read More

Is dasatinib effective with chemotherapy in the treatment of Philadelphia-chromosome postitive ALL?

Posted by on Jun 9, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effect of dasatinib (Sprycel) in addition to intensive chemotherapy in the treatment of children and young adults with acute lymphoblastic leukemia (ALL). The study concluded that dasatinib with chemotherapy was a safe and effective way to treat ALL. Some background Acute lymphoblastic leukemia (ALL) is a...

Read More

Radiotherapy for relapsed or refractory diffuse large b-cell lymphoma

Posted by on May 29, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...

Read More

Is tandem stem cell transplantation effective in high risk relapsed/refractory Hodgkin lymphoma

Posted by on May 26, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...

Read More

Can chronic myeloid leukemia patients discontinue dasatinib after a year of deep molecular response?

Posted by on May 12, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...

Read More

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Posted by on May 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...

Read More